A 50-year-old woman in Tainan who turned to unregulated weight-loss injections suffered a devastating wake-up call when her persistent vomiting—dismissed as a drug side effect—was actually a symptom of advanced gastric and gallbladder cancers that had spread to four organs. The case has prompted urgent warnings from physicians about the dangers of self-medicating with so-called “slimming shots” without proper medical oversight.
A Risky Shortcut
Standing 160 cm tall and weighing 60 kg, the woman had a healthy BMI of 23.4 and no chronic illnesses. In January 2023, she began purchasing a GLP-1 receptor agonist—commonly known as a “slimming shot”—through online channels without a prescription. She self-administered 2.5 mg weekly for three months, but when the scale didn’t budge and she experienced only mild nausea, she took matters into her own hands.
In late April, she doubled her dose to an unofficial 3.75 mg, after which her symptoms escalated dramatically. Persistent nausea, violent vomiting, and severe appetite loss took hold, yet she continued to attribute her distress to medication side effects.
The Critical Discovery
Over the following weeks, the woman visited multiple clinics and emergency rooms but never disclosed her self-medication. Doctors misdiagnosed her with acute gastroenteritis or drug intolerance. In early June, she collapsed and was rushed to Chi Mei Hospital, where tests revealed critically low sodium and potassium levels alongside an abnormal electrocardiogram.
After hospitalization—and persistent vomiting that defied treatment—doctors performed gastroscopy, CT scans, and biopsies. The diagnosis was devastating: gastric cancer and gallbladder adenoma carcinoma complicated by gastric outlet obstruction. Cancer cells had already metastasized to her liver, adrenal glands, lymph nodes, and lungs.
Dr. Wei-Fu Huang, an endocrinologist at Chi Mei Hospital, emphasized that the vomiting was not caused by the weight-loss drug but by the physical blockage of the stomach outlet caused by the spreading tumors.
Expert Guidance on Proper Use
Dr. Huang stressed that the patient’s normal BMI made her ineligible for these medications under current medical guidelines. Approved indications require either a BMI of 30 or above, or a BMI of 27 or higher with weight-related comorbidities such as hypertension or diabetes.
“Using these drugs at a normal BMI is not only medically unnecessary but carries all the side effects without any expected benefit,” Dr. Huang explained. He noted that while GLP-1 agonists can produce meaningful weight loss of 5-15% in appropriate candidates—improving metabolic markers and cardiovascular risk—they are not “get-slim-quick” tools.
Three Never-to-Ignore Principles
In response to this case, Dr. Huang outlined critical safety guidelines:
- Never buy: Avoid all online and unregulated sources for injectable medications
- Never hide: Always disclose all medications—including self-purchased drugs—to healthcare providers
- Never push through: Stop self-escalating doses and seek medical evaluation if expected results don’t appear
Red Flag Warning Signs
Dr. Huang cautioned that symptoms persisting for more than one month after stopping the drug—particularly vomiting that worsens over time—cannot be attributed to medication side effects and require thorough investigation.
The case serves as a sobering reminder that the pursuit of rapid weight loss can mask life-threatening conditions. Those considering any weight management intervention should undergo proper medical evaluation and treatment planning, ensuring that the quest for a slimmer body never compromises the most valuable asset of all: one’s health.